HPV 2010 - Monday

^L

P-421: Adjunctive HPV ISH test to Hemotoxylin and Eosin Staining to Aide in Diagnosis of Cervical Intraepithelial Neoplasia within Cervical Biopsy Tissue

Wenjun Zhang
Tucson, USA

Add to my agenda

^L

P-689: END-OF-STUDY RESULTS OF PATRICIA: A PHASE III EFFICACY STUDY OF HPV-16/18 AS04-ADJUVANTED VACCINE IN YOUNG WOMEN

Jorma Paavonen [Abstract]
Helsinki, Finland

Add to my agenda

^L

P-400: Persistence of anal HPV infection in HIV-infected patients despite immune restoration under cART

Ali Si-Mohamed [Abstract]
Paris, France

Add to my agenda

^L

P-401: Anal cancer is preventable through treatment of high-grade anal intra-epithelial neoplasia

Mayura Nathan [Abstract]
London, United Kingdom

Add to my agenda

^L

P-402: Topical Cidofovir for Treatment of High-Grade Perianal Intraepithelial Neoplasia in HIV-Infected Men and Women

Elizabeth A. Stier [Abstract]
Boston, USA

Add to my agenda

^L

P-403: Risk factors for abnormal anal cytology in HIV-infected women

Elizabeth A. Stier [Abstract]
Boston, USA

Add to my agenda

^L

P-404: The detection of HPV genotypes in anal cancer biopsy specimens from Sydney, Australia

Richard Hillman [Abstract]
Westmead, Australia

Add to my agenda

^L

P-405: Progression and regression of anal squamous intra-epithelial lesions (ASIL) in patients participating in an anal screening program

Richard Hillman [Abstract]
Westmead, Australia

Add to my agenda

^L

P-406: Prospective Study of Topical 5-Fluorouracil Treatment of Anal Intraepithelial Neoplasia in HIV-Positive Men

Olivier Richel [Abstract]
Amsterdam, The Netherlands

Add to my agenda

^L

P-407: Outcome of Conservative Surgical Management of Superficially Invasive Squamous Cell Carcinoma of the Anus

J. Michael Berry [Abstract]
San Francisco, USA

Add to my agenda

^L

P-408: Efficacy, Safety and Tolerability of Argon Plasma Coagulation to treat Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-seropositive MSM

Alexandra de Pokomandy [Abstract]
Montreal, Canada

Add to my agenda

^L

P-409: High acceptability of self-collected anal swabs and High Resolution Anoscopy (HRA)

Leon P. Botes [Abstract]
Westmead, Canada

Add to my agenda

^L

P-410: Episomal and integrated HPV-16 loads in anal intraepithelial neoplasia in HIV-seropositive men

Jennifer Alvarez [Abstract]
Terrebonne, Canada

Add to my agenda

^L

P-411: Recurrence of High Grade Anal Intraepithelial Neoplasia and Cancer in Patients Treated with Combined Modality Therapy for Anal Cancer

Naomi Jay [Abstract]
San Francisco, USA

Add to my agenda

^L

P-412: Prevalence and associations of anal human papillomavirus (HPV) infection in African-Caribbean (AC) women in Toronto, Canada

Anuradha Rebbapragada [Abstract]
Toronto, Canada

Add to my agenda

^L

P-413: Prevalence and associations of vaginal human papillomavirus (HPV) infection in African-Caribbean (AC) women in Toronto

Anuradha Rebbapragada [Abstract]
Toronto, Canada

Add to my agenda

^L

P-414: Performance of HPV testing and anal cytology to detect high-grade anal intraepithelial neoplasia in men who have sex with men

Ina Park [Abstract]
Richmond, USA

Add to my agenda

^L

P-415: DNA Methylation Profiling Across the Spectrum of HPV-Associated Anal Squamous Neoplasia

Jonathan Hernandez [Abstract]
Tampa, USA

Add to my agenda

^L

P-416: Cervical infection by multiple Human Papillomavirus (HPV) genotypes: Correlation with colposcopy and histopathology

Neerja Bhatla [Abstract]
Associate Professor of Obstetrics & Gynaecology, All India Institute of Medical Sciences
New Delhi, India

Add to my agenda

^L

P-417: cobas 4800 HPV Test Performance for >CIN2 and >CIN3 detection in women with ASC-US : ATHENA results

Mark Stoler [Abstract]
Professor of Pathology, Cytology and Gynecology, Associate Director of Surgical Pathology and Cytopathology, Director of Gynecological Pathology Fellowship Program, Department of Pathology,University of Virginia
Charlottesville, USA

Add to my agenda

^L

P-418: HR HPV mRNA Detection using APTIMA Specimen Collection

Max Chernesky [Abstract]
Emerritus Professor, Pediatrics and Pathology, St. Joseph's Healthcare
Hamilton, Canada

Add to my agenda

^L

P-420: Enzyme Immunoassays for detection of HPV E6/E7 oncoproteins in cervical cancer

Shu-Ling Cheng [Abstract]
Fremont, USA

Add to my agenda

^L

P-421: Adjunctive HPV ISH Test to Hemotoxylin and Eosin Staining to Aide in Diagnosis of Cervical Intraepithelial Neoplasia within Cervical Biopsy Tissue

Wenjun Zhang [Abstract]
Tucson, USA

Add to my agenda

^L

P-423: Infection and cancers caused by Human Papllomavirus in Bangladesh

Abdul Mottaleb [Abstract]
Dhaka, Bangladesh

Add to my agenda

^L

P-425: Generation of Pan-HPV E4 antibodies as biomarkers of active HPV infections

Zhonglin Wu [Abstract]
London, UK

Add to my agenda

^L

P-426: Type-specific E4 antibodies as virus-specific biomarkers of infection and disease severity in CIN

Zhonglin Wu [Abstract]
London, UK

Add to my agenda

^L

P-427: Occurrence of selected urogenital infections in HPV positive women in Eastern Slovakia.

Jozef Adam [Abstract]
Ko?ice, Slovakia

Add to my agenda

^L

P-428: P16INK4a and ProExC in HPV-associated squamous intraepithelial lesions of the cervix

Manuela Pelmus [Abstract]
Sherbrooke, Canada

Add to my agenda

^L

P-429: Comparison of liquid-based with conventional cytology for detection of cervical neoplasia

Joanna Swiderska [Abstract]
Warsaw, Poland

Add to my agenda

^L

P-430: Determinants of multiple lesions and lesion size in a large series of LEEPs

Hannah Yang [Abstract]
Rockville, USA

Add to my agenda

^L

P-431: MCM2/TOP2a testing in cervical cancer screening: A multicentre Canadian study

D. Fontaine [Abstract]
St John's, Canada

Add to my agenda

^L

P-432: Management of women with low-grade cytological abnormalities: a comparison of triage options

Maria Kyrgiou [Abstract]
London, UK

Add to my agenda

^L

P-433: Management of women with high-grade cytological abnormalities: a comparison of triage options

Maria Kyrgiou [Abstract]
London, UK

Add to my agenda

^L

P-434: DETECTION OF HPV DNA IN CERVICAL SAMPLES OF WOMEN FROM RIO DE JANEIRO, BRAZIL, SUBMITTED TO COLPOSCOPY

Amanda Pinto [Abstract]
Rio de Janeiro, Brazil

Add to my agenda

^L

P-435: An HPV Genotyping assay that utilizes QIAGEN hybrid capture technology

Ha Thai [Abstract]
Gaithersburg, USA

Add to my agenda

^L

P-436: Multicenter evaluation of the cobas 4800 HPV test: Detection of CIN2+ lesions compared to hc2

M.T. Sandri [Abstract]
Milano, Italy

Add to my agenda

^L

P-437: Can HPV DNA/mRNA and/or p16 status reduce the need for biopsies in pregnant women with atypical cytology?

Cecilia Kärrberg [Abstract]
Gothenburg, Sweden

Add to my agenda

^L

P-438: EXPRESSION OF RAP1 AND P16INK4A IN CERVICAL PRENEOPLASTIC AND NEOPLASTIC LESIONS ASSOCIATED WITH HIGH RISK HUMAN PAPILLOMAVIRUS INFECTION

Jaquelline Oliveira [Abstract]
Belo Horizonte, Brazil

Add to my agenda

^L

P-439: Biological activity of rare HR-HPV in cervical cancer

Gordana Halec [Abstract]
Heidelberg, Germany

Add to my agenda

^L

P-440: HPV involvement in larynx carcinoma

Gordana Halec [Abstract]
Heidelberg, Germany

Add to my agenda

^L

P-441: PDIP38 as a marker for progression of high-risk HPV-16 associated cervical dysplasia

Eugene Toy [Abstract]
Rochester, USA

Add to my agenda

^L

P-442: Genotyping of human papillomavirus in gynecologic outpatients of Mérida, western Venezuela

José-Andrés Mendoza [Abstract]
Mérida, Venezuela

Add to my agenda

^L

P-443: Serum p16INK4a levels in cervical cancer patients

Miriam Reuschenbach [Abstract]
Heidelberg, Germany

Add to my agenda

^L

P-444: Combined staining of cervical lesions for p16INK4a and Ki67 distinguishes cervical dysplasia from metaplasia

Mirjam Seiz [Abstract]
Heidelberg, Germany

Add to my agenda

^L

P-445: The comparison between the performance of morphological versus molecular oncological diagnosis

Frank Karlsen [Abstract]
Klokkarstua, Norge

Add to my agenda

^L

P-446: An E6 oncoprotein based diagnostic test for cervical pre-cancer and cancer

Johannes Schweizer [Abstract]
Fremont, USA

Add to my agenda

^L

P-447: Comparison between Bio-Rad HR-HPV Dx PCR Assay and Hybrid Capture® 2

Christine Clavel [Abstract]
Professor in Cellular Biology, Centre Hospitalier Universitaire de Reims
Reims, France

Add to my agenda

^L

P-448: Performance and acceptability of the vaginal self-collected sample for careHPV(TM) testing in Nicaragua

Jose A. Jeronimo [Bio] [Abstract]
Director START-UP Project, Reproductive Health, PATH
Seattle, USA

Add to my agenda

^L

P-450: Randomized controlled trial of primary HPV testing in a Canadian organized screening program

Gina Ogilvie [Bio] [Abstract]
Associate Medical Director, Division of STI/HIV Prevention and Control, BC Centre for Disease Control
Vancouver, Canada

Add to my agenda

^L

P-451: Predicting future risk of CIN2+: HPV DNA vs. mRNA tests

Sam Ratnam [Abstract]
Director, Newfoundland Public Health Laboratory
St. John's, Canada

Add to my agenda

^L

P-452: CINtec p16INK4a cytology, APTIMA HPV mRNA, and HC2 HPV DNA test to identify high grade cervical dysplasia

Magnus von Knebel Doeberitz [Abstract]
Director and Professor, Department of Applied Tumor Biology, University of Heidelberg Im Neuenheimer
Heidelberg, Germany

Add to my agenda

^L

P-453: Evaluation of adjunct primary screening with cytology and HPV testing by HC2, Aptima(TM) HPV, Abbott® RT or Cervista(TM) HPV.

Carlos Sousa [Abstract]
Porto, Portugal

Add to my agenda

^L

P-454: AGREEMENT BETWEEN THE ABBOTT REALTIME HIGH RISK HPV TEST AND THE HYBRID CAPTURE 2 IN DETECTION OF HR HPV AND DIAGNOSIS OF HIGH-GRADE CERVICAL DISEASE

Francesca Maria Carozzi [Abstract]
Florence, Italy

Add to my agenda

^L

P-455: Microarray-in-microwell HPV Profiling of Atypical Squamous cells of Undetermined Significance in an Asian Screening Population

Oscar G.W. Wong [Abstract]
Hong Kong, China

Add to my agenda

^L

P-456: CLINICAL VALIDATION OF COBAS 4800 HPV TEST FOR CERVICAL SCREENING

Danielle Heideman [Abstract]
Amsterdam, The Netherlands

Add to my agenda

^L

P-457: Comparative analysis of CBG HPV HR assay and HC2 assay

Hee Jae Joo [Abstract]
Department of Pathology, Ajou University Hospital
Suwon, Korea

Add to my agenda

^L

P-458: HUMAN PAPILLOMA VIRUS (HPV) POPULATION SCREENING PROGRAM IN OVIEDO, A REGION IN SPAIN

María de-Oña [Abstract]
Oviedo, Spain

Add to my agenda

^L

P-459: HUMAN PAPILLOMAVIRUS INFECTION IN A MEN POPULATION ATTENDING A SEXUAL TRANSMISSION INFECTIONS SERVICE

María de-Oña [Abstract]
Oviedo, Spain

Add to my agenda

^L

P-460: Sensitivity of the Abbott RealTime High Risk HPV test for detection of high risk HPV infection and disease

Vanja Kaliterna [Abstract]
Split Dalmatia, Croatia

Add to my agenda

^L

P-461: Digital analysis of IHC images for detecting HPV E6/E7 oncoproteins in CIN2/3 and cervical cancer tissues

Shu-Ling Cheng [Abstract]
Fremont, USA

Add to my agenda

^L

P-462: the importance of colposcopy and hpv tipization in screening for cervical cancer in developing countries

Alma Tedeschini [Abstract]
Durres, Albania

Add to my agenda

^L

P-463: Comparison of the Roche cobas 4800 vs. Qiagen hc2 Tests for Detection of High-Risk HPV DNA

Kathy Ceballos [Abstract]
Vancouver, Canada

Add to my agenda

^L

P-464: Introduction of careHPV in rural Nigeria: Methodologic lessons and analysis of performance

Kayode Olusegun Ajenifuja [Abstract]
Ile-Ife, Nigeria

Add to my agenda

^L

P-465: PROMOTER METHYLATION OF CADM1 AND MAL IS AN ALTERNATIVE FOR CYTOLOGY TO TRIAGE HRHPV-POSITIVE WOMEN

Bart Hesselink [Abstract]
Amsterdam, The Netherlands

Add to my agenda

^L

P-466: Role of HPV typing and p16 immunostaining in triage of epithelial abnormalities of the cervix

Vanita Suri [Abstract]
Chandigarh, India

Add to my agenda

^L

P-467: Prevalence of HPV genotypes in cervical cancer in Saudi Arabia

Ghazi Alsbeih [Abstract]
Riyadh, Saudi Arabia

Add to my agenda

^L

P-468: Analytical performances of the Bio-Rad HR-HPV Dx PCR Assay

Laurent Jain [Abstract]
Marnes la coquette, France

Add to my agenda

^L

P-469: Risk factors for severe cervical dysplasia after ascus and hsil pap tests

Lisa Spiryda [Abstract]
Columbia, USA

Add to my agenda

^L

P-470: Sarcoidosis of the cervix: an unusual case presentation

Lisa Spiryda [Abstract]
Columbia, USA

Add to my agenda

^L

P-471: Comparison of liquid-based cytology and HPV DNA testing: a pooled-analysis of 18 population-based studies from China

Margaret Lin [Abstract]
Beijing, China

Add to my agenda

^L

P-472: The male contribution to the female vaginal swab: possible implications for HPV testing.

Marc Baay [Abstract]
Wilrijk, Belgium

Add to my agenda

^L

P-473: Intracellular HPV e6, e7 mRNA quantification predicts cin 2,3 in biopsies better than pap screening

Bruce K. Patterson [Abstract]
Campbell, USA

Add to my agenda

^L

P-474: ANALYTICAL AND CLINICAL PERFORMANCE OF A NEW MOLECULAR HPV ASSAY

Laurence Vaughan [Abstract]
Sparks, USA

Add to my agenda

^L

P-475: Detection of high-risk HPV mRNA in liquid based cytology (LBC) specimens with the APTIMA® HPV Assay

Andreas Clad [Abstract]
Freiburg, Germany

Add to my agenda

^L

P-476: Evaluation of the clinical performance of the CLART HPV 2 assay in comparison with the Hybrid Capture 2

Angela Pista [Abstract]
Lisboa, Portugal

Add to my agenda

^L

P-477: Primary HPV Testing in a Canadian Population-based Screening Program

Ogilvie Gina [Abstract]
Vancouver, Canada

Add to my agenda

^L

P-478: Pre-vaccination prevalence of human papillomavirus types in the genital tract of 15-23 year old women in a youth clinic in Stockholm, Sweden

Juan Du [Abstract]
Stockholm, Sweden

Add to my agenda

^L

P-479: Concordance between Introital and Cervical samples for Human Papillomavirus status and type

Alexandra Sargent [Abstract]
Manchester, UK

Add to my agenda

^L

P-480: Evaluation of the Cervical DNA Dtex® test for detecting cervical disease in cytology normal, HPV positive patients

Gregory Endress [Abstract]
Rockville, USA

Add to my agenda

^L

P-481: Evaluation of Cervical DNA Dtex® for stratification of patients with abnormal cervical cytology and HPV positivity

Madhvi Upender [Abstract]
Rockville, USA

Add to my agenda

^L

P-482: High-risk HPV prevalence among HSIL subjects in the United States

Warner Huh [Abstract]
Birmingham, USA

Add to my agenda

^L

P-483: Study of human papillomavirus testing in cervical cancer screening

Toshiyuki Maehama [Abstract]
Tomigusuku, Japan

Add to my agenda

^L

P-484: Assessment of a self-lavaging device for Human Papillomavirus prevalence testing in women 20 to 30 years of age in Germany

Andreas M. Kaufmann [Abstract]
Berlin, Germany

Add to my agenda

^L

P-485: HPV 16/18 typing versus HPV screening in low grade cytology

Heather A. Cubie [Abstract]
Edinburgh, UK

Add to my agenda

^L

P-486: HPV in triage of low grade abnormalities within MAVARIC

Heather A. Cubie [Abstract]
Edinburgh, UK

Add to my agenda

^L

P-487: Reliability, validity and acceptability of self-lavaging (Delphi Screener(TM)) for cervical cytology and HPV testing

Heidi E. Jones [Abstract]
New York, US

Add to my agenda

^L

P-488: Significance of HPV mRNA testing and cigarette smoking in predicting high grade cervical disease.

Christine White [Abstract]
Dublin, Ireland

Add to my agenda

^L

P-489: HPV prevalence and persistence in a cohort of HIV positive women in Ireland

Christine White [Abstract]
Dublin, Ireland

Add to my agenda

^L

P-490: The role of p16INK4a immunocytochemistry for detection of cervical intraepithelial lesions

Manuela Pelmus [Abstract]
Sherbrooke, Canada

Add to my agenda

^L

P-491: Clinical management guidelines based on risk of cervical precancer or cancer

Hormuzd Katki [Abstract]
Rockville, USA

Add to my agenda

^L

P-492: Hybrid capture assay performance of liquid-based cytology specimens after sample preparation by the automated QIAensemble(TM) SP

Suganthi Ramachandran [Abstract]
Gaithersburg, USA

Add to my agenda

^L

P-493: Comparison of Manual and Automated Methods for Isolation of RNA from BD SurePath(TM) Liquid-Based Pap Specimens

Melissa Adams [Abstract]
Durham, USA

Add to my agenda

^L

P-494: Expression of mRNA of COX-1 and COX-2 in SIL of uterine cervix and its association with the Human Papilloma Viruses

Berenice Illades-Aguiar [Abstract]
Chilpancingo, México

Add to my agenda

^L

P-495: Self-collected vaginal specimens: Acceptance and usefulness for HPV detection

Berenice Illades-Aguiar [Abstract]
Chilpancingo, México

Add to my agenda

^L

P-496: Evaluation of liquid based cytology in the detection of early lesions in the uterine cervix

Marco Antonio Leyva-Vázquez [Abstract]
Chilpancingo, México

Add to my agenda

^L

P-497: Cyclins A and E in low grade squamous intraepithelial lesions with high risk human papillomavirus

Marco Antonio Leyva-Vázquez [Abstract]
Chilpancingo, México

Add to my agenda

^L

P-498: Top IIA/Mcm 2 expression and human papiloma virus DNA in cervical cones

Marco Antonio Leyva-Vázquez [Abstract]
Chilpancingo, México

Add to my agenda

^L

P-499: Ki-67 expression in low grade squamous intraepithelial lesions with high risk human papillomavirus

Marco Antonio Leyva-Vázquez [Abstract]
Chilpancingo, México

Add to my agenda

^L

P-500: the utility of urinary HPV DNA detection for the presence of high grade cervical intra-epithelial neoplasia

Anne-Laure Grignon [Abstract]
Cambridge, UK

Add to my agenda

^L

P-501: QIAsymphony® AXpH protocol for use with SurePath® cervical specimens

Christian Kupfer [Abstract]
Gaithersburg, USA

Add to my agenda

^L

P-502: Evaluation of Cervical Inflammatory Cells as a Biomarker for Screening

Troy Querec [Abstract]
Atlanta, USA

Add to my agenda

^L

P-503: Low-grade squamous intraepithelial lesions: results from the Cervista® HPV HR clinical trial

Michael A. Gold [Abstract]
Nashville, USA

Add to my agenda

^L

P-504: Risk stratification for cervical intraepithelial neoplasia in women referred to colposcopy

Julia Gargano [Abstract]
Atlanta, USA

Add to my agenda

^L

P-505: Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in cervical samples

Dominic O'Neil [Abstract]
Gaithersburg, U.S.A

Add to my agenda

^L

P-506: Multiplexed HPV genotyping assay using isothermal whole genome amplification

Holly Basham [Abstract]
Gaithersburg, USA

Add to my agenda

^L

P-507: QIAensemble(TM) 2000: A Next-generation High-throughput Platform for Human Papillomavirus DNA Assays

Jianrong Lou [Abstract]
Gaithersburg, USA

Add to my agenda

^L

P-508: Low-risk HPV Typing of Cervical Specimens Using GP+ PCR with Multiplex Detection on Luminex ® XMAP® Technology

Lori Kobayashi [Abstract]
Gaithersburg, USA

Add to my agenda

^L

P-509: Multicenter evaluation of the cobas 4800 HPV test: Analytical comparison to hc2

M.L. Lindemann [Abstract]
Madrid, Spain

Add to my agenda

^L

P-510: Lessons from cervical cancer screening in Bamako (Mali) between 2001 and 2009.

Ibrahima Téguété [Abstract]
Bamako, Mali

Add to my agenda

^L

P-511: HPV genotyping in a population of the Catalonian cervical cancer screening

Jose M. Godínez [Abstract]
Barcelona, Spain

Add to my agenda

^L

P-512: HPV detection in cervico-vaginal self-samples using a solid carrier: the Indicator FTA elute cartridge

Roosmarie de Bie [Abstract]
Nijmegen, The Netherlands

Add to my agenda

^L

P-513: The proportion of human papillomavirus type 16 increases along with the grade of cervical intraepithelial neoplasia

Yong-Sang Song [Abstract]
Seoul, Republic of Korea

Add to my agenda

^L

P-514: The proportion of human papillomavirus type 16 increases along with the grade of abnormal cervical cytology

Yong-Sang Song [Abstract]
Seoul, Republic of Korea

Add to my agenda

^L

P-515: Comparison of PNA based array with DNA-based array for detecting and genotyping Human Papillomavirus

Chung Won Lee [Abstract]
SEOUL, REPUBLIC OF KOREA

Add to my agenda

^L

P-516: Paramount consideration of primary screening algorithms

Hanne Skomedal [Abstract]
Klokkarstua, Norway

Add to my agenda

^L

P-517: Evaluation of self collected compared to brush samples from cancer patients and in routine settings

Hanne Skomedal [Abstract]
Klokkarstua, Norway

Add to my agenda

^L

P-518: Specific methylation of WNT/?-catenin pathway regulators in cervical adenocarcinomas

Renske D.M. Steenbergen [Abstract]
Amsterdam, The Netherlands

Add to my agenda

^L

P-519: Comparative Analysis of ABSOLUTE HPV HR Assay and Hybrid Capture 2 Assay in Cervical Samples

Sang Yeop Yi [Abstract]
Goyang-si, South KOREA

Add to my agenda

^L

P-520: Self-sampling HPV testing program among women never attended screening in six counties in Taiwan.

Yun-Yuan Chen [Abstract]
Taipei, Taiwan

Add to my agenda

^L

P-521: Effect of vaginal self-sampling on cervical cancer screening rates: a community-based study

Pauline Duke [Abstract]
St. John's, Canada

Add to my agenda

^L

P-522: Comparison of Analytical Sensitivities of 3 Commercial Assays for HPV Detection

Kate Cuschieri [Abstract]
Edinburgh, United Kingdom

Add to my agenda

^L

P-523: A novel expression biomarker set has high accuracy to predict CIN1+ lesions using routine cervical cytology specimens

Csaba Jeney [Abstract]
Budapest, Hungary

Add to my agenda

^L

P-524: field trial of screening options for cervical cancer in chile: preliminary results

Solana Terrazas [Abstract]
Santiago, Chile

Add to my agenda

^L

P-525: Nucleic acid-sequence based amplification assay for HPV mRNA detection and typing: evidence for DNA amplification

Isabel Micalessi [Abstract]
Antwerp, Belgium

Add to my agenda

^L

P-526: Colposcopy vs. HPV testing to identity persistent pre-cancers post treatment: the CoHIPP trial

Marie-Hélène Mayrand [Bio] [Abstract]
Chercheur, Faculté de médecine, Départements de Gynécologie et de Médecine Sociale et Préventive, Université de Montréal et CHUM
Montréal, Canada

Add to my agenda

^L

P-527: NFk B EXPRESSION IN CERVICAL DYSPLASIA AND CANCER IN SMEARS - A C0RRELATION WITH HPV POSITIVITY

A.N. Srivastava [Abstract]
Department of Pathology, Era's Lucknow Medical College & Hospital
Lucknow, India

Add to my agenda

^L

P-528: Significance of Human Papillomavirus Genotyping in the Prognosis of Early-stage Cervical Carcinoma

Seok Mo Kim [Abstract]
Department of Ob/Gyn, School of Medicine, Chonnam Naational University
Gwangju, Korea

Add to my agenda

^L

P-530: microRNA profiles of cervical tissues and identification of mir-29 as HPV related miRNAs

Yang Li [Abstract]
hang zhou, China

Add to my agenda

^L

P-531: A novel ablative therapy using phenol for cervical intraepithelial lesions and condyloma acuminata

Toshiyuki Sasagawa [Abstract]
Kahoku-gun, Japan

Add to my agenda

^L

P-532: HPV and Cervical Cancer Testing and Prevention: investigating the Barriers among young women in a Rural Uganda Trading Centre - a qualitative study

Sheeba Kastiro [Abstract]
Kampala, Uganda

Add to my agenda

^L

P-533: Effects of Photodynamic Therapy using topically applied Hexylaminolevulinate and Methylaminolevulinate upon the Integrity of Cervical Tissue

Peter Hillemanns [Abstract]
Hannover, Germany

Add to my agenda

^L

P-534: Focused Ultrasound for Therapeutic Molecules Delivery in human papillomavirus-related cancers.

Sarah Lane [Abstract]
Thunder Bay, Canada

Add to my agenda

^L

P-535: HR-HPV Infections and Telomerase Activity like to predict risk of High Grade Cervical Lesions. A Follow-up study

Monica Molano [Abstract]
Bogotá, Colombia

Add to my agenda

^L

P-536: HPV POSITIVITY AND TELOMERASE h - TERT EXPRESSION IN LSIL/ HSIL CERVICAL SMEARS: A HIGH RISK INDICATOR

Shruti Srivastava [Abstract]
Lucknow, India

Add to my agenda

^L

P-537: Cervical cancer epidemiology in the malian teaching hospitals during two decades

Ibrahima Téguété [Abstract]
Bamako, Mali

Add to my agenda

^L

P-538: Methyl jasmonate is cytotoxic to cervical cancer cells that contain or lack HPV DNA

Levana Sherman [Abstract]
Tel-Aviv, Israel

Add to my agenda

^L

P-539: DETECTION OF PERSISTENT CIN2+ AFTER TREATMENT: ROLE OF HPV 16 GENOTYPING

Mario Sideri [Abstract]
Milan, Italy

Add to my agenda

^L

P-540: Cytology vs Visual Inspection with Acetic Acid in Women Previously Treated With Cryotherapy

Miriam Cremer [Abstract]
New York, USA

Add to my agenda

^L

P-541: HPV type distribution in skin carcinomas and actinic keratoses from renal transplant patients

Belen Lloveras [Abstract]
Barcelona, Spain

Add to my agenda

^L

P-542: History of genital warts and self-reported health in 45,000 Danish men and women

Maria Blomberg [Abstract]
Copenhagen, Denmark

Add to my agenda

^L

P-543: Head and neck cancer incidence in Denmark, 1978-2007 - focus on HPV associated sites

Maria Blomberg [Abstract]
Copenhagen, Denmark

Add to my agenda

^L

P-544: Imiquimod 2.5% and 3.75% applied daily for up to 8 weeks to treat external genital warts

Daron Ferris [Abstract]
Augusta, USA

Add to my agenda

^L

P-545: Distribution of human papillomavirus (HPV) genotypes in tissue specimens of Slovenian patients with laryngeal papillomas

Boštjan J. Kocjan [Abstract]
Ljubljana, Slovenia

Add to my agenda

^L

P-546: HPV types in juvenile respiratory papillomatosis and in cervicovaginal specimens in a USA County

Hector Zambrano [Abstract]
New Haven, USA

Add to my agenda

^L

P-547: Intratype variation of complete HPV 6 genomes in laryngeal and pharyngeal papillomas

Agustin Enrique Ure [Abstract]
Malmö, Sweden

Add to my agenda

^L

P-548: Understanding the psychosocial burden of genital warts in Canada: A prospective 6-month study

Melanie Drolet [Abstract]
Quebec, Canada

Add to my agenda

^L

P-549: DETECTION AND GENOTYPING OF CUTANEOUS HUMAN PAPILLOMAVIRUS

Rita Correa [Abstract]
Ciudad Autónoma de Buenosa Aires, Argentina

Add to my agenda

^L

P-550: Ecologic study of HPV genera indicates the oral cavity is a reservoir of abundant known and novel beta and gamma HPV types

Robert David Burk [Abstract]
Professor, Department of Pediatrics (Genetics), Department of Microbiology & Immunology, Department of Obstetrics & Gynecology and Women's Health (Gynecological Oncology), Department of Epidemiology & Population Health and Vice Chair for Translational Res
Bronx, USA

Add to my agenda

^L

P-551: Phase I clinical trial of intralesional injection of Candida antigen for treating warts

Kevin Kim [Abstract]
Department of Pathology, College of Medicine, University of Arkansas for Medical Sciences,
Little Rock, USA

Add to my agenda

^L

P-552: Skin wart-associated HPV types: prevalence and relation with patient characteristics and cure rates in primary care

Sjoerd Bruggink [Abstract]
Leiden, The Netherlands

Add to my agenda

^L

P-553: Epidermodysplasia verruciformis: An immunohistochemical approach from one case report

Alcina F. Nicol [Abstract]
Rio de Janeiro, Brazil

Add to my agenda

^L

P-554: HPV-related skin cancer: ongoing reports.

Aldo Venuti [Abstract]
Rome, Italy

Add to my agenda

^L

P-555: Human papillomavirus infection and squamous cell carcinoma of the conjunctiva

Elisabete Weiderpass [Abstract]
Oslo, Norway

Add to my agenda

^L

P-556: Persistent betapapillomavirus infections in organ transplant recipients

M.N.C. de Koning [Abstract]
Voorburg, The Netherlands

Add to my agenda

^L

P-557: HPV genotype distribution in cutaneous and genital warts is different in HIV infected patients

M.N.C. de Koning [Abstract]
Voorburg, The Netherlands

Add to my agenda

^L

P-558: Multiplex genotyping of 58 cutaneous HPV types

Michael Pawlita [Abstract]
Heidelberg, Germany

Add to my agenda

^L

P-559: Case-control study of cutaneous HPV serology, DNA positivity and cutaneous squamous cell carcinoma

Dana Rollison [Abstract]
Tampa, USA

Add to my agenda

^L

P-560: Identification of a novel human gamma-papillomavirus (HPV126) with EV-Like eruption in a patient with ATL.

Nagayasu Egawa [Abstract]
Chuo-ku, Japan

Add to my agenda

^L

P-561: HPV prevalence in skin warts detected by novel multiplex genotyping

Daniela Höfler [Abstract]
Heidelberg, Germany

Add to my agenda

^L

P-562: Optimized protocol for skin swab sampling

Tim Waterboer [Abstract]
Heidelberg, Germany

Add to my agenda

^L

P-563: A comparison of clinically utilized HPV detection methods in head and neck squamous cell carcinoma (HNSCC)

Nicolas F. Schlecht [Abstract]
Newark, USA

Add to my agenda

^L

P-564: IgA immune response in saliva induced by HPV-16/18 vaccine

Young Tae Kim [Abstract]
Seoul, Korea

Add to my agenda

^L

P-565: HIGH RISK HPV POSITIVITY AND h- TERT EXPRESSION IN ORAL CANCER

Vandana Tiwari [Abstract]
LUCKNOW, INDIA

Add to my agenda

^L

P-566: EVER2 genetic variation alters risk of HPV-related head and neck squamous cell carcinoma

Heather Nelson [Abstract]
Minneapolis, USA

Add to my agenda

^L

P-567: HPV genotypes in 122 head and neck squamous cell carcinomas

Jaana Rautava [Abstract]
Turku, Finland

Add to my agenda

^L

P-568: p16INK4a overexpression predicts translational active human papillomavirus infection in tonsillar cancer

Markus Hoffmann [Abstract]
Kiel, Germany

Add to my agenda

^L

P-569: Biomarker expression in HPV positive head and neck cancers: an institutional experience

P.K. Ganguly [Abstract]
St. John's, Canada

Add to my agenda

^L

P-570: Human papillomavirus in oral squamous cell carcinomas

Daniela Cochicho [Abstract]
Lisbon, Portugal

Add to my agenda

^L

P-571: Human papillomavirus 16/18 prevalence in oropharyngeal and oral cavity cancers from 5 US cancer registries

Jennifer Wai Lee [Abstract]
Atlanta, USA

Add to my agenda

^L

P-572: HPV-associated survival and response to therapy in head and neck cancer

Christian R. Salazar [Abstract]
New York, US

Add to my agenda

^L

P-573: Oral and anal HPV infection among HIV-infected men and women

Anil Chaturvedi [Abstract]
Rockville, USA

Add to my agenda

^L

P-574: International trends in incidence for HPV-related head and neck cancer sites

Anil Chaturvedi [Abstract]
Rockville, USA

Add to my agenda

^L

P-575: Estimated population-level burden of HPV-positive oropharynx cancers among smokers and never smokers in the United States

Anil Chaturvedi [Abstract]
Rockville, USA

Add to my agenda

^L

P-576: HPV in head and neck cancers: a worldwide study protocol

Laia Alemany [Abstract]
L'Hospitalet de Llobregat, Spain

Add to my agenda

^L

P-577: Comparison of two linear array assays for defining HPV genotypes in oral and oropharyngeal squamous cell carcinomas

Rebecca Shanesmith [Abstract]
Oklahoma City, USA

Add to my agenda

^L

P-578: Human papillomavirus infection and p16INK4a expression in the oropharynx

Elena Prigge [Abstract]
Heidelberg, Germany

Add to my agenda

^L

P-579: CD8+ T-cell count significantly effects the natural history of HPV & SIL in HIV+ women

Howard Strickler [Abstract]
Professor, Epidemiology & Population Health, Albert Einstein College of Medicine
Bronx, USA

Add to my agenda

^L

P-580: HPV multiple infections in HIV positive women in Italy

Anna Rosa Garbuglia [Abstract]
Rome, Italy

Add to my agenda

^L

P-581: Genital HPV infection in a group of Portuguese women infected with HIV

Margarida Bernardino [Abstract]
Lisboa, Portugal

Add to my agenda

^L

P-582: Pap tests after hysterectomy in HIV positive women: At risk for VAIN 2/3 and cancer?

Mary Carol Jennings [Abstract]
Columbia, USA

Add to my agenda

^L

P-583: major risk factors in hpv detection in unisex immunosupressed-cohorts

Ajobiewe Olu Joseph [Abstract]
ABUJA, NIGERIA

Add to my agenda

^L

P-584: HPV prevalence and type distribution among HIV positive Tanzanian women

Myassa Dartell [Abstract]
Copenhagen, Denmark

Add to my agenda

^L

P-585: Sensitivity of cervical HPV testing for CIN2+ in HIV-Infected women with ASC-US cytology

Gypsyamber D'Souza [Abstract]
Baltimore, USa

Add to my agenda

^L

P-586: High risk HPV in HIV positive women on HAART: Study from North India

Ritu Aggarwal [Abstract]
Chandigarh, India

Add to my agenda

^L

P-587: Genetic variations in the interleukin-7 gene (IL7) associated with clearance of HPV infection in HIV-1-infected individuals

Sadeep Shrestha [Abstract]
Birmingham , USA

Add to my agenda

^L

P-588: Rapid Increase in HPV Detection after HIV Seroconversion

Chunhui Wang [Abstract]
Fort Lee, USA

Add to my agenda

^L

P-589: Male HIV infection and sexual characteristics as risk factors for cervical precancerous lesions among female partners.

Anne F. Rositch [Abstract]
Chapel Hill, USA

Add to my agenda

^L

P-590: HPV INFECTION AND ITS ASSOCIATED RISK FACTORS IN LUPUS WOMEN UNDER LONG-TERM USE OF IMMUNOSUPRESSORS

Jacyara Macedo [Abstract]
Rio de Janeiro, Brazil

Add to my agenda

^L

P-591: High incidence of high-grade anal intraepithelial neoplasia in HIV-infected women and men following organ transplantation

Peter V. Chin-Hong [Abstract]
San Francisco, USA

Add to my agenda

^L

P-592: HPV infection among men ages 25-65 years in Anyang, China

Yang Ke [Bio] [Abstract]
Professor of Oncology, Executive Vice President of Peking University, Executive Vice President of Peking University Health Science Center
Beijing, China

Add to my agenda

^L

P-593: High-risk sexual behaviour in a random sample of >22,000 men from the general population in Denmark

Nina Buttmann [Abstract]
København, Denmark

Add to my agenda

^L

P-594: Incidence of genital warts among men in the placebo arm of a quadrivalent HPV vaccine trial

Stephen Goldstone [Abstract]
Department of Surgery, Mount Sinai School of Medicine
New York, USA

Add to my agenda

^L

P-595: The changing picture of anal dysplasia screening with time and increased experience

Stephen Goldstone [Abstract]
Department of Surgery, Mount Sinai School of Medicine
New York, USA

Add to my agenda

^L

P-596: Infra-red coagulator ablation of anal dysplasia men: Results of long-term follow-up

Stephen Goldstone [Abstract]
Department of Surgery, Mount Sinai School of Medicine
New York, USA

Add to my agenda

^L

P-597: A case assignment methodology for determining qHPV vaccine efficacy against anal intraepithelial neoplasia

Stephen Goldstone [Abstract]
Department of Surgery, Mount Sinai School of Medicine
New York, USA

Add to my agenda

^L

P-598: HPV prevalence and risk factors among young heterosexual men and men who have sex with men

Henrike J. Vriend [Abstract]
Bilthoven, The Netherlands

Add to my agenda

^L

P-599: Risk factors and age-specific prevalence for anal HPV among men having sex with women and men having sex with men

Alan G. Nyitray [Abstract]
Tampa, USA

Add to my agenda

^L

P-600: Type-specific incidence and persistence of anal HPV in men after six months of follow up: The HIM study

Alan G. Nyitray [Abstract]
Tampa, USA

Add to my agenda

^L

P-601: Cross-national genital HPV prevalence among men having sex with men and men having sex with women: The HIM study

Alan G. Nyitray [Abstract]
Tampa, USA

Add to my agenda

^L

P-602: Clinical characterization and treatment of penile intraepithelial neoplasia grade 1, 2 and 3

Arne Wikström [Abstract]
Stockholm, Sweden

Add to my agenda

^L

P-603: Evaluation of human papillomavirus infection in male urinary tract using urine samples by a lquid-based cytology method

Shohei Kawaguchi [Abstract]
Kanazawa, Japan

Add to my agenda

^L

P-604: Oral and Serum Antibodies and Genital HPV in South African Men

Dianne Marais [Abstract]
Cape Town, South Africa

Add to my agenda

^L

P-605: PERSISTENT HPV INFECTIONS IN MULTIPLE GENITAL SPECIMENS IN MEN

Lucia Giovannelli [Abstract]
Palermo, Italy

Add to my agenda

^L

P-606: Prevalence and characteristics of anal HPV infection among HIV-negative men who have sex with men (MSM)

Massimo Giuliani [Abstract]
Rome , Italy

Add to my agenda

^L

P-607: Long-term follow-up and E6/E7 oncogenic activation in HPV-DNA positive asymptomatic males

Sandra Mazzoli [Abstract]
Firenze, Italy

Add to my agenda

^L

P-608: Risk Factors for HPV Related External Genital Lesions in Men: The HIM Study

Gabriella Anic [Abstract]
Tampa, United States

Add to my agenda

^L

P-609: Molecular characterization of Human Papillomavirus type 16, -18, -31, -33 and -52 variants in HIV1-positive and -negative men who have sex with men

Montserrat Torres [Abstract]
Majadahonda, Spain

Add to my agenda

^L

P-610: HPV PREVALENCE AMONG MEN WHO HAVE SEX WITH MEN (MSM) AND TRANS SEX WORKERS (TSW) IN BUENOS AIRES, ARGENTINA.

M. Alejandra Picconi [Abstract]
Ciudad Autonoma de Buenos Aires, Argentina

Add to my agenda

^L

P-611: Risk factors associated with colposcopy-detected penile lesions in Kenyan men

Danielle M. Backes [Abstract]
Durham, USA

Add to my agenda

^L

P-612: Concordance and transmission of human papillomavirus

Lea Widdice [Abstract]
Cincinnati, U.S.A

Add to my agenda

^L

P-613: HPV oncogene mRNA detection is suitable for the diagnosis of anal dysplasia in HIV-infected men

Steffi Silling [Abstract]
Koeln, Germany

Add to my agenda

^L

P-614: Detection of HPV DNA in Urine and Oral Samples of HIV-1 male in Sao Paulo, Brazil.

Fernando Costa [Abstract]
Sao Paulo, Brazil

Add to my agenda

^L

P-615: hpv prevalence and genotypes distribution among Italian sexual partners

Maria Benevolo [Abstract]
Rome, Italy

Add to my agenda

^L

P-616: Human papillomavirus infection in couples undergoing in-vitro fertilization procedures: impact on reproductive outcome

A. Perino [Abstract]
Palermo, Italy

Add to my agenda

^L

P-617: Seropositivity for HPV type 16 antibodies and its association with HPV infection and precancerous cervical lesions: Results from the Ludwig-McGill Coh

Ramanakumar V. Agnihotram [Abstract]
Montreal, Canada

Add to my agenda

^L

P-618: New sex partners and menopausal stage are predictors of prevalent HR-HPV in women aged 35-60 years

Patti Gravitt [Bio] [Abstract]
Assistant Professor, Epidemiology; Molecular Microbiology and Immunology, John Hopkins Bloomberg School Of Public Health(JHSPH)
Baltimore, USA

Add to my agenda

^L

P-619: High HPV seroprevalence in perimenopausal women attending routine GYN care in Baltimore, MD

Patti Gravitt [Bio] [Abstract]
Assistant Professor, Epidemiology; Molecular Microbiology and Immunology, John Hopkins Bloomberg School Of Public Health(JHSPH)
Baltimore, USA

Add to my agenda

^L

P-620: The spectrum of HPV genotypes in cervical cancer in Uganda

Charles JN Lacey [Bio] [Abstract]
Professor of Medicine & Honorary Reader in Sexual Health and HIV Medicine, The Hull York Medical School
York, United Kingdom

Add to my agenda

^L

P-621: Cofactors of HR-HPV infections display unique profiles in incident CIN1, CIN2 and CIN3

Kari Syrjanen [Abstract]
Professor, Department of Oncology and Radiotherapy, Turku University Hospital
Turku, Finland

Add to my agenda

^L

P-622: Evidence for the protective effect of condoms against male-to-female transmission

Ann Burchell [Bio] [Abstract]
Division of Cancer Epidemiology, Departments of Oncology and Epidemiology and Biostatistics, McGill University
Montreal,

Add to my agenda

^L

P-623: Estimation of HPV clearance time and related factors in Korean women

Chan Joo Kim [Abstract]
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Paul's Hospital, The Catholic University of Korea
Seoul, Korea

Add to my agenda

^L

P-624: Prevalence of human papilloma virus infection among normal pregnant women in Korea

Yun Hwan Kim [Abstract]
Department of Obstetrics and Gynecology, Seoul National University Hospital
Seoul, Korea

Add to my agenda

^L

P-625: Prevalence of human papilloma virus infection among normal pregnant women in Korea

Yun Hwan Kim [Abstract]
Department of Obstetrics and Gynecology, Seoul National University Hospital
Seoul, Korea

Add to my agenda

^L

P-626: Cofactors in human papillomavirus cervical carcinogenesis

Kirsten E. Jensen [Abstract]
Department of Viruses, Hormones and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society
Copenhagen, Denmark

Add to my agenda

^L

P-627: Koilocytosis in Cervical Smears: Long term hospital based cytological screening program

Jata Misra [Abstract]
Lucknow, India

Add to my agenda

^L

P-628: The role of circulating antioxidants on high risk human papillomaviruses infection and cervical carcinogenesis

Kyeong A. So [Abstract]
Seoul, Korea

Add to my agenda

^L

P-629: Genotype-specific natural history of cervical HPV infections among mothers in the Finnish Family HPV Study

Karolina Louvanto [Abstract]
Turku, Finland

Add to my agenda

^L

P-630: Semi-Markov Two-State Modeling of HPV Persistence

Cicely Mitchell [Abstract]
Durham, USA

Add to my agenda

^L

P-631: HPV Infections are Common in Young Women with Negative Cervical Cytology

Mark Evans [Abstract]
Burlington, USA

Add to my agenda

^L

P-632: DISTRIBUTION OF HUMAN PAPILLOMAVIRUS TYPE 58 VARIANTS IN PROGRESSION OF CERVICAL DYSPLASIA IN KOREAN WOMEN

Jong Sup Park [Abstract]
SEOUL, REPUBLIC OF KOREA

Add to my agenda

^L

P-633: Combination of CO2 Laser Therapy and Artificial Dermis Application in Plantar Warts: HPV DNA Analysis After Treatment

Tsuyoshi Mitsuishi [Abstract]
Tokyo, Japan

Add to my agenda

^L

P-634: Concordance of HPV types and HPV-16 variants between genital sites and fingernail tips in young men

Matthew Thomas [Abstract]
Seattle, United States

Add to my agenda

^L

P-635: Evaluation of a generic assay for the screening of pgmy-generated hpv amplicons

Véronique Legault [Abstract]
Montréal, Canada

Add to my agenda

^L

P-636: Cut primer system: an additional tool to study human papillomavirus infections in mucosal and cutaneous epithelia

Diego Chouhy [Abstract]
Rosario, Argentina

Add to my agenda

^L

P-637: HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix.

Edyta C. Pirog [Abstract]
New York, USA

Add to my agenda

^L

P-638: HPV genotypes in cervical lesions of screened women. Comparison between Italian and NIS countries.

Anna Paaso [Abstract]
Turku, Finland

Add to my agenda

^L

P-639: Viral load is associated with prevalent HSIL especially for HPV16 - results from a study of more than 40,000 Danish women

Christian Munk [Abstract]
Copenhagen, Denmark

Add to my agenda

^L

P-640: Bacterial vaginosis in cervical lesion and cancer development in an HIV-seropositive population

Sheri A. Denslow [Abstract]
Carrboro, USA

Add to my agenda

^L

P-641: Marked differences in Betapapillomavirus markers between psoriasis and atopic dermatitis patients

M.N.C. de Koning [Abstract]
Voorburg, The Netherlands

Add to my agenda

^L

P-642: Genital and extra-genital warts increase the risk of asymptomatic genital HPV infection in men

Brenda Hernandez [Abstract]
Honolulu, U.S.A.

Add to my agenda

^L

P-643: Rapid fluctuation in the detection of genital HPV in male-female couples

Brenda Hernandez [Abstract]
Honolulu, U.S.A.

Add to my agenda

^L

P-644: HPV16 variant lineage, stage at diagnosis, and prognosis in women with invasive cervical cancer

Rosemary Zuna [Abstract]
Oklahoma City, USA

Add to my agenda

^L

P-645: Impact of CpG Methylation of HPV16 Genome on Viral Transcription and Risk of Cervical Intraepithelial Neoplasia

Zhenping Shen [Abstract]
Seattle, USA

Add to my agenda

^L

P-646: Evaluation, in Portugal, of Genital Diseases associated with the human papillomavirus (HPV)

Daniel Silva [Abstract]
Coimbra, Portugal

Add to my agenda

^L

P-647: Quantitative Assessment of Epigenetic Alterations in Cervical Cancer: Potential Screening Markers?

Erin Siegel [Abstract]
Tampa, USA

Add to my agenda

^L

P-648: The relationship between biomarkers of oxidant load and type-specific human papillomavirus clearance

Erin Siegel [Abstract]
Tampa, USA

Add to my agenda

^L

P-649: Hr HPV but no betaPV types detected in penis in-situ cancers

W.G.V. Quint [Abstract]
Voorburg, The Netherlands

Add to my agenda

^L

P-650: Skin wart associated HPV types remain detectable in swabs after warts have resolved

W.G.V. Quint [Abstract]
Voorburg, The Netherlands

Add to my agenda

^L

P-651: Longitudinal analysis of type-specific HPV infection, viral load, and cytologic abnormality in the Guanacaste Cohort

Sarah Coseo [Abstract]
Rockville, United States

Add to my agenda

^L

P-652: Absolute risk of CIN2+ after re-appearance of same carcinogenic HPV type

Ana Cecilia Rodriguez [Abstract]
San Jose, Costa Rica

Add to my agenda

^L

P-653: The percentage (%) and severity of cytologic abnormalities vary by HPV genotype: a population-wide analysis

Carolina Porras [Abstract]
Rockville, United States

Add to my agenda

^L

P-654: Anti-retroviral Therapy Increases the Risk of Oral HPV-32 Infection

Michael Hagensee [Abstract]
New Orleans , USA

Add to my agenda

^L

P-656: Human Papillomavirus Type 16 DNA Load and Risk of Cervical Intraepithelial Neoplasia: A Nested Case-Control Study

Long Fu Xi [Abstract]
Seattle, USA

Add to my agenda

^L

P-657: Anal HPV Infection mirrors Cervical Infection with EBV Co-shedding associated with Increased Anal HPV shedding.

Kerstan Stuckey [Abstract]
New Orleans, Louisiana

Add to my agenda

^L

P-658: Low level persistence of HPV 16 infection in adolescent women

Aaron Ermel [Abstract]
Indianapolis, USA

Add to my agenda

^L

P-659: antibody response in women with naturally acquired hpv16 infection using pseudovirion-based neutralization assay

Gitika Panicker [Abstract]
Atlanta, USA

Add to my agenda

^L

P-660: Detection of genital HPV types in fingernail samples from newly sexually active female university students

Rachel Winer [Abstract]
Seattle, USA

Add to my agenda

^L

P-661: Duration of human papillomavirus and other sexually transmitted infections in adolescent women

Bree Weaver [Abstract]
Indianapolis, USA

Add to my agenda

^L

P-662: Analysis of HPV genotype patterns in ALTS using unsupervised hierarchical clustering

Lauren Wilson [Abstract]
Rockville, USA

Add to my agenda

^L

P-663: Concurrent infection with multiple high risk human papillomavirus types among female sex workers in Kenya

Suha Patel [Abstract]
Raleigh, USA

Add to my agenda

^L

P-664: Human papillomavirus, cervical neoplasia and impact of HIV-1 infection among female sex workers in Kenya

Nelly Mugo [Abstract]
Nairobi, Kenya

Add to my agenda

^L

P-665: HPV6/11 detection and p16-INK4A expression in Anogenital carcinomas.

Núria Guimerà [Abstract]
L'Hospitalet de Llobregat, Spain

Add to my agenda

^L

P-666: Associations between cervical epithelial immaturity, rate of metaplasia, and HPV 16 acquisition

Loris Hwang [Abstract]
San Francisco, USA

Add to my agenda

^L

P-667: Rapid reduction of cervical cancer in developing countries

Julian Peto [Abstract]
Keppel Street, UK

Add to my agenda

^L

P-668: Comparison of HPV Linear Array and cobas® 4800 system results with eluted DNA from x480 Sample Preparation - Kaiser PaP pilot study

Carrie Aldrich [Abstract]
Pleasanton, USA

Add to my agenda

^L

P-669: Quadrivalent HPV vaccine efficacy against ana HPV infection in men having sex with men

Anna R. Giuliano [Bio] [Abstract]
Chair, Department of Cancer Epidemiology and Genetics; Program Leader, Risk Assessment, Detection, and Intervention Program; H. Lee Moffitt Cancer Center and Research Institute
Tampa, USA

Add to my agenda

^L

P-670: Lower level of titers in response to the HPV quadrivalent vaccine among men who have sex with men compared with heterosexual men

Joel Palefsky [Bio] [Abstract]
Professor of Medicine, UCSF School of Medicine
San Francisco, USA

Add to my agenda

^L

P-671: High reproducibility of oral rinse and gargle (ORG) alone for detection of type-specific oral HPV infection

Maura Gillison [Abstract]
Columbus, United States

Add to my agenda

^L

P-672: Reactogenicity of alternative schedules of Gardasil® vaccine to prevent human papillomavirus (HPV) infection

D. Scott LaMontagne [Abstract]
Seattle, USA

Add to my agenda

^L

P-673: Immunogenicity of alternative schedules of Gardasil® in 11-13-year-old girls in Vietnam

D. Scott LaMontagne [Abstract]
Seattle, USA

Add to my agenda

^L

P-674: Safety and tolerability of the quadrivalent HPV vaccine in men aged 16 to 26

Edson Moreira [Abstract]
Bahia, Brazil

Add to my agenda

^L

P-675: Would HPV vaccination help prevent HIV acquisition?

Randall Hyer [Abstract]
Tokyo, Japan

Add to my agenda

^L

P-676: ErbB-2 receptor cooperates with E6/E7 onco-proteins of HPV type 16 in breast carcinogenesis

Riccardo Ricciardi [Abstract]
Montreal, Canada

Add to my agenda

^L

P-677: Prevention of HPV reinfection with HPV vaccination after laser vaporisation and conisation in patients with HSIL

Nino Museridze [Abstract]
Tbilisi, Georgia

Add to my agenda

^L

P-678: HPV Antibody Responses Among Subjects Enrolled in a 2- vs. 3-dose HPV Vaccine Trial

Mel Krajden [Abstract]
Vancouver, Canada

Add to my agenda

^L

P-679: Co-administration of Gardasil and Twinrix to 9-10 year-old girls preliminary immunogenicity data

Vladimir Gilca [Bio] [Abstract]
Quebec , Canada

Add to my agenda

^L

P-680: Computer-aided Vaccine Design via SimNanoWorld(TM): An HPV Demonstration

Kyle McWilliams [Abstract]
Bloomington, USA

Add to my agenda

^L

P-681: Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases in Women: A Systematic Review & Meta Analysis

Beibei Lu [Abstract]
TAMPA, USA

Add to my agenda

^L

P-682: Detection of HPV 31 and 58 cross-neutralizing antibodies in HPV 16 vaccinated subjects.

Pierre Coursaget [Abstract]
TOURS, FRANCE

Add to my agenda

^L

P-683: COMPARISON OF TWO HIGH-THROUGHPUT SEROLOGICAL METHODS FOR HUMAN PAPILLOMAVIRUSES

Helena Faust [Abstract]
Malmö, Sweden

Add to my agenda

^L

P-684: Adjuvant immunotherapy for persistent genital warts

Ian Frazer [Bio] [Abstract]
Director, Diamantina Institute for Cancer, Immunology and Metabollic Medicine (DI)
Buranda, Australia

Add to my agenda

^L

P-685: Correlation between Pathology, HPV Detection and p16 Immunostaining in Primary Squamous Cell Carcinoma of the Vagina

Immaculada Alonso [Abstract]
Barcelona, Spain

Add to my agenda

^L

P-686: Clinical and molecular characterization of small vulvar cancer of the anterior fourchette

Monika Hampl [Abstract]
Duesseldorf, Germany

Add to my agenda

^L

P-687: Squamous cell carcinoma of the vulva: significance of HPV infection

Jaume Ordi [Abstract]
Barcelona, Spain

Add to my agenda

^L

P-688: DISTRIBUTION OF HPV GENOTYPES IN SLOVENIAN PATIENTS WITH ANAL AND PERIANAL WARTS

Kristina Fujs Komloš [Abstract]
Ljubljana, Slovenia

Add to my agenda

^L

P-690: A TWO DOSE HPV VACCINE SCHEDULE IN GIRLS: IMMUNOGENICITY AT 24 MONTHS

Simon Dobson [Abstract]
Associate Infection Control Officer, BC Women’s Hospital & Health Centre; Clinical Associate Professor, University of Newcastle
Vancouver, Canada

Add to my agenda

^L

P-691: Distribution of human papillomavirus type 16 E6 and E7 gene variants in the progression of cervical dysplasia

Soo Young Hur [Abstract]
SEOUL, REPUBLIC OF KOREA

Add to my agenda

^L

P-692: Comparative immunogenicity of two prophylactic human papillomavirus vaccines: results through Month 24

Archana Chatterjee [Abstract]
Omaha, USA

Add to my agenda

^L

P-694: ANY CORELLATION BETWEEN KOILOCYTES(HPV INDICATORS) AND CD4 CELLS IN UNISEX -HIV POSITIVE COHORTS?

Ajobiewe Olu Joseph [Abstract]
ABUJA, NIGERIA

Add to my agenda

^L

Human Papillomavirus genotype detection in Recurrent Respiratory Papillomatosis (RRP) in Colombia

Gloria Ines Sanchez [Abstract]
Medellin, Colombia

Add to my agenda

About the Agenda Builder

HPV 2010

Programme

>> Poster Viewing - Clinical Sciences

About the Agenda Builder

HPV 2010 Programme

>> Poster Viewing - Clinical Sciences

HPV 2010

Programme